Groupe Athena Inc (PINK:GATA)

MUMBAI, India, Feb. 12, 2013 /PRNewswire/ -- Groupe Athena, Inc. (OTCPink: GATA) announced today record revenues of $14,810,936 for the period ending December 31, 2012, which represents a 23% increase over the same period in 2011. Net after tax income for the period was $1,549,882 or $.033 per share which was also the best for any quarter to date as profit margins continue to increase.

Revenue growth for the first half of this fiscal year is also on a record pace and has increased approximately 30% year on year. With the two recent strong quarters trailing twelve month (ttm) earnings have increased to just over $.11 per share.

Cash reserves are strong and long term debt remains virtually non-existent as the Company prepares to outfit it's recently purchased new testing facility. The company reports it is still committed to funding all capital expenditures entirely from internal cash accruals without any shareholder dilution or debt increases.

Company Chairman, D. Purohit stated, "We could not be happier with our financial position and the pharmaceutical business environment in general. Many of our regional customers are now renewing contracts going forward and our efforts to develop and expand our global footprint is progressing nicely."

As previously stated, the company plans to apply for listing on the NASDAQ Bulletin Board quotation system with the completion of the audit for this fiscal year ending June 30, 2013.

MUMBAI, India, Nov. 14, 2012 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets: GATA) announced today record revenues of $15,367,544 for the first quarter ending September 30, 2012, which is a 25% increase over the same period in 2011. Net after tax income for the period was $1,307,293 or $.03 per share which included a one time expense of $407,181 related to the purchase of the company's new facility in India. Trailing twelve month (ttm) earnings remained strong at nearly $.10 per share. The company also has a very healthy cash position and no long term debt.

The Company's Chairman, D. Purohit stated, "The pharma industry within our region is still very robust and Groupe Athena is extremely well positioned to continue on our current growth track for the foreseeable future. And with the recently reported asset additions which allow us to perform more services in-house, our margins are also increasing significantly."

In other news the Company has completed their recent transition from GAAP to the International Financial Reporting Standard (IFRS) for all future audited financials. The Company's annual report for the recent fiscal yearend on June 30, 2012 which was released on August 20, 2012 was audited using IFRS. With the completion of the audit for this fiscal year end on June 30, 2013 the company will seek to qualify for listing on the NASDAQ Bulletin Board quotation system.

MUMBAI, India, Aug. 27, 2012 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets: GATA) has announced record revenues of $44,571,386 for the recent fiscal year ended June 30, 2012, an increase of 78% over the previous year. After tax earnings increased 116% to a record $4,417,047 or $0.094 a share.

Though the company added $4,656,442 in assets, its cash position is extremely healthy with cash and short term assets of $3,286,141 as against current liabilities of $84,090. The company is proud of the fact that all equipment and other acquisitions have been made entirely from internally generated cash and it is the commitment of management that future additions to the asset base be accomplished without any further dilution or debt increases. The Company has no plans for shareholder dilution over the next 12-18 months.

MUMBAI, India, April 11, 2012 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets GATA.PK) announced they have released their financial results for the third quarter which ended March 31, 2012.  Total revenue for the period was $10,378,928 which is 140% greater than the same period in 2011. Net income rose to $1,184,000 compared to $731,644.

For the nine months the company also reported record revenue of $34,558,560 compared to $17,893,325. Net income for the first three quarters of the current fiscal year has more than doubled to $3,524,218 or $.075 per fully diluted share.

The company's cash increased to more than $3.5 million including the special escrow for the anticipated new facility acquisition. They are extremely excited to have been able to maintain this healthy cash position while still adding $3.61 million worth of new equipment in the last 12 months with no shareholder dilution or assumption of debt.

The company reiterates the recent guidance update which stated annualized revenue should increase to exceed $44 million. Earnings are also expected to increase similarly.

MUMBAI, India, Feb. 28, 2012 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets GATA.PK) announced today it has reported revenues of $11,968,232 for the recent fiscal quarter ended December 31, 2011, which combined with the 1st quarter of this fiscal year established record 6 months revenue and earnings. Total revenues for the 6 month period were $24,179,632 which exceeded any period of the same length in the company's history and nearly equaled the total revenues for the entire 2011 fiscal year.  After tax earnings also increased for the same period to $2,529,725 or $.054 per share.

The Company's Chairman, D. Purohit stated, "India's pharmaceutical industry is experiencing unprecedented growth and Groupe Athena, Inc. is uniquely poised to capitalize.  As many critical drug patents expire for large U.S. manufacturers, it opens many doors for us here. This is an exciting time to be part of our dynamic revenue growth and we look forward to further similar increases as we continue to gain market share and increase our participation in the explosive growth of our core industry."

The Company's debt to equity ratio also remains extremely healthy at over 40 to 1 with cash and short term assets of $3,530,864 and total assets of $8,650,722 as of December 31 and only $114,232 of current liabilities and $0 long term debt on the books. The company is proud of the fact that all equipment and other acquisitions have been made entirely from internally generated cash and it is the commitment of management that future additions to the asset base be accomplished without any further dilution or debt increases. The Company has no plans for shareholder dilution over the near term.

First quarter 2012 Results

•  Record revenues of $12,211,400 for the first quarter ending September 30, 2011 
•  Pretax earnings of $1,566,906, or $.033 per share which is also a record for the same period.

 With the most recent strong quarter, trailing twelve month (ttm) earnings jumped to nearly $.10 per share. The record quarterly revenue was significant in that it equaled nearly 50% of total revenue for all of the previous fiscal year.

The Company's Chairman, D. Purohit stated, "As our markets continue to expand within India and the region, we expect to see continued strong revenue and earnings growth, and with the recently reported asset additions which allow us to perform more services in-house, our margins are also increasing significantly. We are also very pleased to have a healthy backlog to build on which currently insures our growth well into fiscal 2013."

We are not sure what to make of this company: Hype or Reality.. But the guidance makes the story worth tracking, especially as shares just attained a new 52 week high of about $0.70

MUMBAI, India, Aug. 24, 2011 /PRNewswire/ -- Groupe Athena, Inc. (Pink Sheets: GATA) announced on August 15, 2011 they have approximately $60 million in customer orders that they are currently processing, and they are expecting this number to increase in the near term. Based on the orders in hand the company expects to be able to convert at least two thirds or approximately $40 million into revenue during the current fiscal year.

The company also stated that due to the recent capital investments in equipment and facilities which has increased their ability to perform more services in-house, they will to be able to increase net profit margins on future revenues by 1.5-2%. To clarify this projection the company issued the following example:

Approximate current hourly rate for outsourcing of tests: $1,750

Approximate In-house hourly rate for same process: $3-400

Based on this scenario the company expects to reduce these costs up to 80% over current levels.

The resulting savings to net earnings would have added several hundred thousand dollars to fiscal 2011 net earnings and will have a positive impact on any future earnings.

The company is on track to report revenue of $12,000,000 for the current quarter, which would be more than the first and second quarters combined of the previous fiscal year and well in line with their expectations for the current fiscal year.

The company is still committed to funding all capital expenditures entirely from internal cash accruals without any further dilution or debt increases.

As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

MUMBAI, India, Aug. 1, 2011 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets GATA.PK) announced today record revenues of $25,112,636 for the recent fiscal year ended June 30, 2011, more than doubling the revenues of the prior fiscal year. After tax earnings also more than doubled for the same period to $2,106,808 or $.045 per share.

The Company's Chairman, D. Purohit stated, "Of course we are very pleased with our current revenue growth and we look forward to further similar increases as we continue to gain market share and increase our participation in the explosive growth of our core industry."

The Company also announced it has a healthy cash position with minimal debt as of June 30, 2011. This is despite the fact that they purchased new equipment worth $445,893 in the third quarter. The purchase was made entirely from internal cash accruals and it is the commitment of management that all future additions to the asset base be from internally generated cash flow only, without any further dilution or debt increases. The Company has no plans for shareholder dilution over the next 24 months.

The company's order position is also very healthy and management expects to announce other related positive financial news in the near term. This is mainly due to the fact that the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company can take on added contracts and continue to anticipate further growth.

GeoTeam Note: 2012 Guidance works out to about EPS of $0.08, fully taxed (June year end)